User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

12630

Interactions with Platform & by Email *

INTERACTIONS

1516

Unique # Participated *

PARTICIPANTS

379

Responses Validated *

VALIDATIONS

41

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
  
   Definitions.....I-4
Biomarker Technologies.....I-4
Emerging Biomarker Technologies.....I-4
Proteomics.....I-4
Transcriptomics.....I-4
  
   Imaging biomarkers.....I-5
Bioinformatics.....I-5
Conventional Biomarker Technologies.....I-5
Molecular Diagnostics.....I-5
Immunodiagnostics.....I-5
Other Biomarker Technologies.....I-5
  
   Metabolite and Enzyme Assays.....I-6
Reagents.....I-6
Biomarker Services.....I-6
Clinical Biomarker Services.....I-6
Biomarker Testing.....I-6
Assay Development and Production.....I-6
Antibody Development.....I-6
Specimen Preparation.....I-6
  
   Bioinformatics and Others.....I-7  
   Global Biomarkers Market Surges in the Backdrop of Widening Medical Scope and
  Applications.....II-8
Factors Engendering Positive Vibes.....II-8
1$100
   Factors Engendering Positive Influence on the Biomarkers Market: A Summary.....II-9
Biomarkers: A Regional Perspective.....II-9
US Spearheads the Global Biomarkers Market.....II-9
US and Japan Take Lead on the Patent Front.....II-9
1$100
   Table 1: Dominance of US in the Global Biomarker Patent Filings (includes corresponding Graph/Chart).....II-10

Table 2: Leading Players in the Biomarkers Space by Number of Patent Filings (includes corresponding Graph/Chart).....II-10
1$350
   Table 3: Number of Biomarker Patents Published and Filed: 2003-2007 (includes corresponding Graph/Chart).....II-11
Asia-Pacific: The Fastest Growing Biomarker Market.....II-11
Supportive Governments and Regulatory Bodies to Fuel Growth.....II-11
1$350
   Increasing Collaborations Among Regulators and Companies Augur Well for
  Biomarkers.....II-12
Player Strategies: An Insight.....II-12
1$100
   Table 4: Growing Number of Biomarker Deals (includes corresponding Graph/Chart).....II-13

Table 5: Competitive Strategy Mix in the Global Oncology Biomarkers Market (includes corresponding Graph/Chart).....II-13
Pharma and Biomarker Developer Tie-Ups to Raise Drug Development Productivity.....II-13
1$350
   Biomarkers: Evolving Scope and Applications.....II-14
Technological Advancements – A Boon for Biomarker Discovery.....II-14
1$100
   Evolving Role of Biomarkers in Drug Development.....II-15
Companion Biomarkers.....II-15
Biomarkers Play Invaluable Role in Oncology and Cardiovascular Disease
  Diagnosis.....II-15
Personalized Medicine- Revolutionizing the Medical Treatment.....II-15
1$100
   Biomarker-Led Drug Discovery – A Profitable Investment.....II-161$100
   Technological Trends.....II-17
Proteins Gain Upper Hand in Biomarkers.....II-17
Mass Spectrometry – A Promising Technology in Molecular Medicine.....II-17
Market Restraints.....II-17
Challenges in Biomarker Validation – A Major Growth Retardant.....II-17
The Road Ahead.....II-17
1$100
   Biomarkers to Witness Significant Growth in Therapeutic and Diagnostic Arenas.....II-181$100
   Efficiency Improvements Must for Realizing Cost-Effective Biomarker Testing.....II-191$100
   Biomarker – Definition & Introduction.....II-20
BIOMARKER TECHNOLOGIES.....II-20
EMERGING BIOMARKER TECHNOLOGIES.....II-20
1$100
   Proteomics.....II-21
Growth Drivers and Market Trends.....II-21
Efficiency Gains in Drug Discovery Drive Growth in Proteomics.....II-21
Proteomics Witness Increased Focus on Targeted Approach.....II-21
Mass Spectrometry –Shifts in Focus to Proteomics Helps Biomarker
  Development.....II-21
1$100
   Mass Spectrometry Expands Scope of Protein Biomarker Applications.....II-22
Transcriptomics.....II-22
Transcriptomics – Assisting in Identification of Biomarkers.....II-22
1$100
   Imaging Biomarkers: Disease Diagnosis, the Non-Invasive way.....II-23
Types of Imaging Biomarkers – An Overview.....II-23
1$100
   Market Trends.....II-24
Molecular Imaging - Gaining Importance in Drug Discovery and Development.....II-24
Use of Molecular Imaging in Clinical Trials for Drug Development.....II-24
Bioinformatics.....II-24
1$100
   CONVENTIONAL BIOMARKER TECHNOLOGIES.....II-25
Molecular Diagnostics.....II-25
Immunodiagnostics.....II-25
Market Trends.....II-25
Growth in Use of Molecular Diagnostics to Propel Biomarker Growth.....II-25
Demand for Novel Biomarkers Persists in Immunodiagnostics.....II-25
1$100
   Immunoassays Plagued with Standardization Issues.....II-26
OTHER BIOMARKER TECHNOLOGIES.....II-26
Metabolite and Enzyme Assays.....II-26
Reagents.....II-26
Market Trends.....II-26
Microarrays Surge Biomarker Identification.....II-26
1$100
   Metabolomics Gain Rapid Foothold in Drug Discovery.....II-27
BIOMARKER SERVICES.....II-27
1$100
   Expanding Capabilities Drive Large-Scale Adoption.....II-28
Clinical Biomarker Services.....II-28
Biomarker Testing.....II-28
Assay Development and Production.....II-28
Antibody Development.....II-28
1$100
   Specimen Preparation.....II-29
Bioinformatics and Other Biomarker Services.....II-29
Bioinformatics Gain Prominence.....II-29
1$100
   miRNA Analysis.....II-30
Microarray Services Witness Increasing Investments.....II-30
1$100
   Role of Biomarkers in Drug Discovery and Development.....II-31
Role of Biomarkers in Clinical Research and Patient Management.....II-31
Major Benefits of Biomarkers in Clinical Development.....II-31
1$100
   Major Benefits of Biomarkers in Medicine.....II-32
Multifarious Applications of Biomarkers.....II-32
New Applications Come to the Fore.....II-32
Application of Biomarkers in Drug Development.....II-32
1$100
   Herceptin and Vilazodone –References for Success of Biomarker Based Approach.....II-33
Increasing Role of Biomarkers in Modern Drug R&D.....II-33
1$100
   Translational Medicine Biomarkers Revolutionizing Drug Development Process.....II-34
Outsourcing - Opportunities Galore.....II-34
CROs in a Dilemma Over Investments in Biomarker Analysis Services.....II-34
1$100
   Lower Productivity of Traditional Drug Discovery Approach Calls for New
  Methods.....II-35
Blockbuster Model Versus Personalized Medication Model.....II-35
1$100
   Workflow Standardization – Key to Success of Biomarkers in Drug Development.....II-361$100
   Current & Future Analysis.....II-37
ONCOLOGY.....II-37
Factors Driving Oncology Biomarkers’ Growth.....II-37
US Remains at the Forefront of Cancer Biomarker Patent Filings.....II-37
1$100
   Table 6: Regional Split in the Global Cancer Biomarker Patent Filings: 2009 (includes corresponding Graph/Chart).....II-38

Table 7: Leading Players in Cancer Biomarkers by Number of Patent Filings: 2004-2009.....II-38
Global Oncology Diagnostics and Drug Discovery Biomarkers Market.....II-38
2$350
   Table 8: World Recent Past, Current and Future Analysis for Oncology Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-401$350
   Table 9: World 10-Year Perspective for Oncology Biomarkers Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-411$350
   Table 10: Global Cancer Biomarkers Diagnostics (Molecular) Market by Company (2009): Market Share Breakdown of Revenues for Roche, Gen-Probe, Myriad, Abbott, QIAGEN and Others (includes corresponding Graph/Chart).....II-42
Evolution of Oncology Biomarkers.....II-42
Available and Pipeline Biomarkers in Various Cancers.....II-42
1$350
   Breast Cancer Dominates Cancer Biomarkers Pipeline.....II-43
Table 11: Global Cancer Biomarkers Pipeline by Indication (2010): Percentage Share Breakdown for Breast Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and Others (includes corresponding Graph/Chart).....II-43
1$350
   Table 12: Global Oncology Biomarkers Market: Percentage Breakdown of Patent Filings by Oncology Area (2007).....II-44
Breast Cancer Market Awaits New Specific Biomarkers.....II-44
Oncology Biomarker Diagnostic Techniques.....II-44
1$350
   Table 13: Leading Cancer Biomarker Diagnostic Technologies (2009): Percentage Share of Value Sales for Gene-based Markers, Proteomics, DNA Microarrays, Immunological Markers and IHC Tests, and Others (includes corresponding Graph/Chart).....II-45
Current Trends in Cancer Biomarkers.....II-45
1$350
   Validation Techniques Take Center Stage.....II-46
Early-Stage Use of Biomarkers High in Oncology.....II-46
Proteomics Ahead of Genomic Biomarkers in Functionality.....II-46
1$100
   Pharmacogenomics and IHC Tests Inch Ahead in Cancer Biomarker Diagnostics.....II-47
Faster Diagnosis Benefits DNA Microarray Technology.....II-47
Other Tests Lose Market Share.....II-47
Companion Biomarkers in Oncology.....II-47
1$100
   CARDIOLOGY.....II-48
Market Trends.....II-48
Increasing Health Burden Drives Research Efforts.....II-48
Gene Expression Analysis Delivers Novel Therapeutic Approaches.....II-48
1$100
   High-Performance Techniques Drive Biomarker Discovery in Cardiology.....II-49
Effective Phenotyping Takes Precedence for Successful Genotyping Studies.....II-49
Role of Linkage Analysis in Cardiovascular Biomarker Identification.....II-49
1$100
   Biomarkers of ACS.....II-50
Biomarkers – A Promising Diagnostic Tool for ACS.....II-50
1$100
   Biomarker Discovery in Cardiovascular Diseases to Undergo Significant
  Changes.....II-51
Major Cardiovascular Diagnostic Biomarkers – A Focus on Biomarkers for ACS.....II-51
Creatine Kinase-Myocardial Band.....II-51
Natriuretic Peptides.....II-51
Cardiac Troponin.....II-51
1$100
   Myoglobin.....II-52
New Diagnostic Biomarkers for ACS on the Anvil.....II-52
1$100
   Genomic Biomarkers for Detecting Cardiovascular Diseases.....II-53
Growing Demand for Stroke Biomarkers.....II-53
Rising Incidence of the Disease – A Major Driver for Stroke Biomarkers.....II-53
CENTRAL NERVOUS SYSTEM (CNS).....II-53
1$100
   Lower Commercial Availability Restricts Market Share.....II-54
Research Efforts Remain Confined to Specific Areas.....II-54
High Cost of Treatment Shadows Biomarkers’ Short-Treatment Benefits.....II-54
Research Methodology in CNS Biomarkers.....II-54
1$100
   Alliances – A Key Aspect to the Development of CNS Biomarkers.....II-55
Biomarkers in Select CNS Diseases.....II-55
Alzheimer's Disease.....II-55
1$100
   Parkinson's Disease Biomarkers - Crucial for Neuroprotectants’ Effectiveness.....II-56
Schizophrenia: An Unexploited Segment.....II-56
OTHER THERAPEUTIC AREAS.....II-56
Inflammatory and Autoimmune Disorders.....II-56
1$100
   Biomarkers offer Efficient Diagnosis and Treatment.....II-57
Rheumatology.....II-57
1$100
   HER2/neu/ ErbB2 Gene.....II-58
HER2 and its Association with Cancer.....II-58
Target Drugs for HER2.....II-58
Hepsin Biomarkers.....II-58
Early Prostate Cancer Antigen-2.....II-58
1$100
   MMP-3.....II-59
ImmunoCyt™/uCyt+™.....II-59
1$100
   AmpliChip CYP450 Test.....II-60
The OncoVue® Breast Cancer Risk Test.....II-60
Oncotype DX® Test.....II-60
Oncotype DX Colon Cancer Assay.....II-60
1$100
   MammaPrint.....II-61
Theros CancerTYPE ID.....II-61
PgxPredict:CLOZAPINE– Test for Qualifying Patients to Use Clozapine.....II-61
1$100
   The Pathwork Tissue of Origin Test.....II-62
PROGENSA PCA3 Assay.....II-62
Epi proColon® Early Detection Assay.....II-62
OVA1® Test.....II-62
1$100
   Bcr-abl Fusion Protein.....II-63
HLA-B.....II-63
Mammostrat®.....II-63
Ipsogen MapQuant Dx™ Genomic Grade.....II-63
CA1-18 Enzyme Immunoassay (EIA).....II-63
1$100
   Anti-L523S Antibody.....II-641$100
   RBM Unveils OncologyMAP® Panel of 101 Quantitative Biomarker Tests.....II-65
Avantra Introduces New BioChip Immunoassay Biomarker Workstation.....II-65
Clarient Introduces Mammostrat Test.....II-65
1$100
   Biomagnetics Diagnostics Identifies Second Biomarker for Tuberculosis Assay.....II-66
Epistem Introduces Novel Ex Vivo Plucked Hair Biomarker Assay.....II-66
Crescendo Bioscience Launches New Multi Biomarker Blood Test.....II-66
Alere International Launches New Triage® NT-proBNP Test.....II-66
1$100
   Agilent Technologies Launches New SureSelect Kinome Target Enrichment Kit.....II-67
Roche Diagnostics to Launch New STAT Immunoassays.....II-67
Gentel Biosciences Launches New Human Profiling Kits.....II-67
1$100
   QIAGEN Introduces QIAsymphony RGQ System.....II-68
Almac Introduces Biomarkers for Biopharmaceutical Industry.....II-68
i-Path Introduces TMA Toolbox.....II-68
1$100
   Abbott Introduces ARCHITECTPLUS Systems.....II-69
Affymetrix Introduces QuantiGene® ViewRNA Assayformats.....II-69
1$100
   ARUP Laboratories Introduces New Test for Colorectal Caner Detection.....II-70
Warnex Launches Blood Testing Service for Colorectal Cancer in Canada.....II-70
Agilent Technologies Launches mAb-Glyco-Chip.....II-70
1$100
   synlab Launches Septin9 Testing in Germany.....II-71
IDBS Introduces New Biomarker Discovery and Validation Solution.....II-71
Quest Diagnostics Introduces Blood Test for Detecting Colorectal Cancer.....II-71
1$100
   Clarient Introduces Biomarker Panel for NSCLC Classification.....II-72
Institute of Microelectronics and Agency for Science, Technology and Research Launch
  Rapid Cardiac Biomarker Test.....II-72
Rules-Based Medicine Unveils CardiovascularMAP™ for CVD Treatment.....II-72
Thermo Fisher Introduces New Copeptin Assay.....II-72
1$100
   Psynova Neurotech and RBM Identify New Biomarkers for Schizophrenia.....II-73
Genedata Unveils Genedata Expressionist® 5.3.....II-73
Arrayit Introduces Biomarker Discovery Service.....II-73
Invitrogen Introduces Biomarker Tool for Kidney Function Research.....II-73
1$100
   Abbott Introduces ARCHITECT® c4000®.....II-74
Epigenomics Rolls Out Epi proColon Range in Europe.....II-74
Genedata Introduces Expressionist 5.2 for Identifying MS-based Biomarker.....II-74
1$100
   VisEn Unveils FAST – A Novel Imaging Platform.....II-75
Millipore and CXR Biosciences Unveils ToxReporter™.....II-75
Rules-Based Medicine Unveils Human Kidney Multi-Analyte Profile.....II-75
MDS and Applied Biosystems Launch AB SCIEX TOF/TOF™ 5800 System.....II-75
1$100
   Genetic Biomarkers for Chronic Kidney Disease.....II-76
Bruker Launches Advanced MALDI-TOF/TOF Mass Spectrometer.....II-76
Satoris Introduces three Novel Blood Tests.....II-76
1$100
   GE Healthcare Launches Discovery™ MR450.....II-77
GE Healthcare in Partnership with Varian Launches Discovery MR901 (US).....II-77
Applied Biosystems and MDS Analytical Launches Novel New Mass Spectrometry
  Tools.....II-77
Rules-Based Medicine Commercializes Rat Kidney MAP Biomarker Panel.....II-77
1$100
   Thomson Reuters Introduces BIOMARKERcenter.....II-78
Gentel® Biosciences Introduces SilverQuant™ GlycoBiomarker Array Kit.....II-78
1$100
   BioMarker Pharmaceuticals Introduces Gene Essence™ DNA Test.....II-79
mtm laboratories Introduces Cervatec™ Assay.....II-79
Decision Biomarkers Introduces AVANTRA Biomarker Workstation.....II-79
1$100
   Aureon Introduces Prostate Px® to Predict Progression and Recurrence of Prostrate
  cancer.....II-80
VisEn Introduces a Novel Imaging Agent.....II-80
1$100
   QIAGEN to Take Over Stake in Alacris Theranostics.....II-81
Transgenomic Acquires Certain Businesses of Clinical Data.....II-81
Caliper Life Sciences Acquires Cambridge Research & Instrumentation.....II-81
1$100
   Biosystems International and MicroBioChips Merge.....II-82
Axela Takes Over Xceed Molecular.....II-82
Accelrys Merges with Symyx Technologies.....II-82
1$100
   Caprion Proteomics Acquires PPD's Biomarker Division.....II-83
QIAGEN Takes Over SABiosciences.....II-83
Thermo Fisher Scientific Takes Over Brahms.....II-83
1$100
   QIAGEN Takes Over DxS.....II-84
ICON Takes Over Veeda Laboratories.....II-84
ID Business Solutions Takes Over InforSense.....II-84
Clinical Data Acquires Avalon Pharmaceuticals.....II-84
1$100
   Genetix Takes Over SlidePath.....II-85
Oxford Gene Technology Takes Over Sense Proteomic.....II-85
Tethys Bioscience Takes Over Lipomics Technologies.....II-85
QPS LLC Acquires Bio-Kinetic Clinical Applications.....II-85
1$100
   AltheaDx Rolls Out Affymetrix DMET Genotyping Microarray Service.....II-861$100
   Proteome Sciences Bags Contract from Eisai.....II-87
MDxHealth to Ink Partnership Agreement with Pfizer, Cancer Research Technology and
  Newcastle University.....II-87
Takeda and Zinfandel Enter into License Agreement for AD Biomarker.....II-87
Pacific Biomarkers Forges Research Deals with Two Multinational Firms.....II-87
1$100
   SMA Foundation and RBM Partner to Develop Panel of SMA Biomarker.....II-88
Epigenomics Enters into Collaboration with QIAGEN to Develop Colorectal Cancer Blood
  Tests.....II-88
Vermillion Inks Agreement with Quest to Launch OVA1® in India.....II-88
DiaGenic and Pfizer Team Up for Identifying Biomarkers for AD.....II-88
1$100
   Prometheus Signs Agreement with The Regents of the University of California.....II-89
Aushon BioSystems Enters into Partnership with LightArray Biotech.....II-89
GE Healthcare Collaborates with Johnson & Johnson.....II-89
1$100
   ICON Enters into Strategic Alliance with Proteome Sciences.....II-90
Epigenomics Inks Distribution Agreement with DATEKS.....II-90
Epigenomics Inks Distribution Agreement with Pronto Diagnostics.....II-90
Thermo Fisher Collaborates with Proteome Sciences.....II-90
1$100
   Diaceutics Teams Up with London Genetics to Develop Software Decision Tools.....II-91
OncoMethylome Enters Into Agreement with GlaxoSmithKline Biologicals.....II-91
SureGene Enters into Research Collaboration with Medco Research Institute.....II-91
1$100
   Ariadne Inks Agreement with Roswell Park Cancer Institute and Cellecta.....II-92
SDIX Enters into Multi-Year Collaboration with Banyan Biomarkers.....II-92
Roche Acquires Co-exclusive License from QIAGEN.....II-92
1$100
   Metabolon Collaborates with Colgate-Palmolive for Periodontal Disease Biomarkers
  Identification.....II-93
Toscana Biomarkers and Regione Toscana Enter into Grant Agreement.....II-93
ACC and Roche Diagnostics Initiate Collaboration.....II-93
Epigenomics Inks Distribution Agreement with DPC LEBANON.....II-93
1$100
   Duke Enters into Joint Venture with LabCorp for Biomarker Commercialization.....II-94
HDC and SPM Enter Into Agreement with Quest Diagnostics.....II-94
Toscana Biomarkers Collaborates with QuantiScientifics.....II-94
1$100
   Intrinsic Bioprobes Licenses New Biomarkers to Ortho-Clinical Diagnostics.....II-95
Shimadzu Allies with Nonlinear Dynamics and Ceres Nanosciences.....II-95
PAREXEL Enters into Partnership with Proteome Sciences.....II-95
Biocartis Inks Agreement with Royal Philips Electronics.....II-95
1$100
   QIAGEN Signs Agreement with Wuxi AppTec.....II-96
SDIX Enters into Collaboration with Fred Hutchinson Cancer Research Center.....II-96
1$100
   Siemens Teams UP with EDPL to Institute Cyclotron Facility in India.....II-97
ALS TDI Concluded First Phase of Collaboration with Applied Proteomics.....II-97
Psynova Neurotech Teams Up with Roche for Schizophrenia Treatment Development.....II-97
1$100
   Minerva Biotechnologies Licenses Exclusive Marketing Rights to Clarient.....II-98
Rules-Based Medicine Signs Biomarker-Driven Agreement with Covance.....II-98
BG Medicine and Abbott Ink Agreement for galectin-3 Biomarker.....II-98
Epigenomics and ARUP Ink Non-Exclusive Agreement.....II-98
1$100
   Biosystems International Signs Licensing Agreement with Lohocla Research.....II-99
Axela Signs Agreements with Micromedics and Proteome Sciences.....II-99
Moffitt Cancer Center and Frantz BioMarkers Enter into Licensing Agreement.....II-99
1$100
   Fujirebio Diagnostics Signs Agreement with BD for Oncology Diagnostic Assays.....II-100
Quest Diagnostics Bags Prostrate Cancer Test License from Epigenomics.....II-100
Genedata Extends Collaboration Agreement with Roche.....II-100
BioTheranostics Inks Commercialization Agreement with Lab 21 for THEROS CancerTYPE
  ID.....II-100
1$100
   Researchers Utilizes AB Sciex Qtrap 5500 System to Detect Biomarkers.....II-101
Fujirebio Inks Agreement with Abbott to Develop Ovarian Cancer Test.....II-101
Caprion and Applied Bioystems Partners to Accelerate Validation and Verification of
  Protein Biomarker.....II-101
Sysmex Inks Research Partnership Deal with Epigenomics.....II-101
1$100
   Pharsight Inks Agreement with InforSense.....II-102
AstraZeneca and Washington University Team Up to Develop Novel Methods for Alzheimer's
  Disease Diagnosis and Treatment.....II-102
1$100
   Genedata Installs Genedata Expressionist® Refiner MS at Victoria DPI.....II-103
Genedata Deploys Genedata Expressionist® at Hospital for Sick Children.....II-103
Covance Establishes New Unit for Discovery and Translation Services.....II-103
The University of Liège Spins-off Targetome Business.....II-103
PMDA Accepts Biomarker Panel of Critical Path’s.....II-103
1$100
   Clarient Obtains UK Patents for the TLE3 Biomarker.....II-104
Agilent Supplies Mass Spectrometry Devices to Stemina Biomarker Discovery.....II-104
Pacific Biomarkers to Launch New Logo, Marketing and Branding Initiatives.....II-104
SMA Foundation Completes Biomarker Study.....II-104
1$100
   Genedata Offers Genedata Expressionist® to RIKEN.....II-105
Chronix Biomedical Strengthens Biomarker Development Capabilities.....II-105
Aureon Changes Name of Colorectal Cancer Prognostic Test.....II-105
Satoris Gains Global Distribution Rights to RBM’s DiscoveryMAP™ Panel.....II-105
1$100
   Teva Pharmaceutical Industries to Use Biomarkers of Compugen.....II-106
Genedata Provides Genedata Expressionist® System to Asubio Pharma.....II-106
InforSense Aids Biomarker Discovery Process by Celera.....II-106
1$100
   Xennex Provides Satoris with Access to GeneCards®.....II-107
IME Developed Silicon-Based Testing System for Cardiac Biomarkers.....II-107
1$100
   Abbott Laboratories (US).....II-108
Affymetrix, Inc. (US).....II-108
1$100
   Agilent Technologies, Inc. (US).....II-109
Alexion Pharmaceuticals, Inc. (USA).....II-109
1$100
   Beckman Coulter, Inc. (US).....II-110
Becton, Dickinson and Company (US).....II-110
Bio-Rad Laboratories, Inc. (US).....II-110
1$100
   BioMérieux (France).....II-111
Bruker Corporation (US).....II-111
1$100
   Caprion Proteomics, Inc. (Canada).....II-112
Clarient Inc. (US).....II-112
1$100
   Compugen, Ltd. (Israel).....II-113
Correlogic Systems, Inc. (US).....II-113
DiagnoCure, Inc. (Canada).....II-113
Epigenomics AG (Germany).....II-113
1$100
   GE Healthcare (UK).....II-114
Gene Logic (US).....II-114
1$100
   Genedata AG (Switzerland).....II-115
Gen-Probe Inc. (US).....II-115
GlaxoSmithKline Plc. (UK).....II-115
1$100
   Hitachi Medical Corporation (Japan).....II-116
Illumina, Inc. (US).....II-116
LabCorp. (US).....II-116
1$100
   Life Technologies Corporation (US).....II-117
Merck & Co., Inc. (US).....II-117
1$100
   Metabolon, Inc. (US).....II-118
Myriad Genetics, Inc. (US).....II-118
Novartis International AG (Switzerland).....II-118
1$100
   Panacea Laboratories (US).....II-119
Pfizer, Inc. (US).....II-119
1$100
   Philips Healthcare (Netherlands).....II-120
QIAGEN NV (The Netherlands).....II-120
1$100
   Quest Diagnostic, Inc. (US).....II-121
Roche Diagnostics Corp. (US).....II-121
Rubicon Genomics, Inc. (US).....II-121
1$100
   Rules-Based Medicine, Inc. (US).....II-122
Siemens Healthcare Diagnostics, Inc. (US).....II-122
1$100
   Table 14: World Recent Past, Current and Future Analysis for Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1231$350
   Table 15: World 10-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1241$350
   Table 16: World Recent Past, Current and Future Analysis for Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1251$350
   Table 17: World 10-Year Perspective for Biomarker Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1261$350
   Table 18: World Recent Past, Current and Future Analysis for Biomarker Technologies by Segment - Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1271$350
   Table 19: World 10-Year Perspective for Biomarker Technologies by Segment - Percentage Breakdown of Dollar Sales for Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1281$350
   Table 20: World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1291$350
   Table 21: World 10-Year Perspective for Emerging Biomarker Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1301$350
   Table 22: World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Segment - Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1311$350
   Table 23: World 10-Year Perspective for Emerging Biomarker Technologies by Segment - Percentage Breakdown of Dollar Sales for Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1321$350
   Table 24: World Recent Past, Current and Future Analysis for Imaging Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1331$350
   Table 25: World 10-Year Perspective for Imaging Biomarkers by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1341$350
   Table 26: World Recent Past, Current and Future Analysis for Proteomics in Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1351$350
   Table 27: World 10-Year Perspective for Proteomics in Biomarker Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1361$350
   Table 28: World Recent Past, Current and Future Analysis for Transcriptomics in Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1371$350
   Table 29: World 10-Year Perspective for Transcriptomics in Biomarkers Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1381$350
   Table 30: World Recent Past, Current and Future Analysis for Bioinformatics in Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1391$350
   Table 31: World 10-Year Perspective for Bioinformatics in Biomarkers Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1401$350
   Table 32: World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1411$350
   Table 33: World 10-Year Perspective for Conventional Biomarker Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1421$350
   Table 34: World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Segment - Immunodiagnostics and Molecular Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1431$350
   Table 35: World 10-Year Perspective for Conventional Biomarker Technologies by Segment - Percentage Breakdown of Dollar Sales for Immunodiagnostics and Molecular Diagnostics Markets for Years 2008, 2011, and 2017 (includes corresponding Graph/Chart).....II-1441$350
   Table 36: World Recent Past, Current and Future Analysis for Immunodiagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1451$350
   Table 37: World 10-Year Perspective for Immunodiagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1461$350
   Table 38: World Recent Past, Current and Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1471$350
   Table 39: World 10-Year Perspective for Molecular Diagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1481$350
   Table 40: World Recent Past, Current and Future Analysis for Other Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1491$350
   Table 41: World 10-Year Perspective for Other Biomarker Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1501$350
   Table 42: World Recent Past, Current and Future Analysis for Biomarker Services by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1511$350
   Table 43: World 10-Year Perspective for Biomarker Services by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1521$350
   Table 44: World Recent Past, Current and Future Analysis for Biomarker Services by Segment - Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1531$350
   Table 45: World 10-Year Perspective for Biomarker Services by Segment - Percentage Breakdown of Dollar Sales for Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1541$350
   Table 46: World Recent Past, Current and Future Analysis for Clinical Biomarker Services by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1551$350
   Table 47: World 10-Year Perspective for Clinical Biomarker Services by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1561$350
   Table 48: World Recent Past, Current and Future Analysis for Specimen Preparation by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1571$350
   Table 49: World 10-Year Perspective for Specimen Preparation by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1581$350
   Table 50: World Recent Past, Current and Future Analysis for Other Biomarker Services by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1591$350
   Table 51: World 10-Year Perspective for Other Biomarker Services by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1601$350
   Table 52: World Recent Past, Current and Future Analysis for Biomarkers by Application - Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1611$350
   Table 53: World 10-Year Perspective for Biomarkers by Application - Percentage Breakdown of Dollar Sales for Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1621$350
   Table 54: World Recent Past, Current and Future Analysis for Biomarkers by Therapeutic Area - Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarkers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-1631$350
   Table 55: World 10-Year Perspective for Biomarkers by Therapeutic Area - Percentage Breakdown of Dollar Sales for Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-1641$350
   A. Market Analysis.....II-165
Current & Future Analysis.....II-165
Companies Wake Up to the Growing Need for Effective Biomarkers.....II-165
Biomarker Regulations in the US.....II-165
1$100
   Product Launches.....II-1669$225
   Strategic Corporate Developments.....II-17513$275
   Focus on Select Major Players.....II-18811$275
   B. Market Analytics.....II-199
Table 56: The US Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-199
2$350
   Table 57: The US 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2011$350
   A. Market Analysis.....II-202
Current & Future Analysis.....II-202
Product Launch.....II-202
Strategic Corporate Developments.....II-202
2$125
   Focus on Select Major Players.....II-2041$100
   B. Market Analytics.....II-205
Table 58: Canadian Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-205
2$350
   Table 59: Canadian 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2071$350
   A. Market Analysis.....II-208
Current & Future Analysis.....II-208
Strategic Corporate Developments.....II-208
1$100
   Hitachi Medical Corporation – A Key Player.....II-2091$100
   B. Market Analytics.....II-210
Table 60: Japanese Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-210
2$350
   Table 61: Japanese 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2121$350
   A. Market Analysis.....II-213
Current & Future Analysis.....II-213
Biopharmaceutical Industry Tunes into Biomarker- Based Drug R&D.....II-213
Biomarker Regulations in Europe.....II-213
1$100
   EMEA’s Experience in Pharmacogenetic Drugs - Still Nascent.....II-214
Uncertain Laws Discourage VC Funding in Europe.....II-214
Uncertainty Continues Among Regulators over Biomarker Validation Levels.....II-214
1$100
   B. Market Analytics.....II-215
Table 62: European Recent Past, Current and Future Analysis for Biomarkers by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-215
1$350
   Table 63: European 10-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2161$350
   Table 64: European Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-2172$350
   Table 65: European 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2191$350
   A. Market Analysis.....II-220
Current & Future Analysis.....II-220
Strategic Corporate Development.....II-220
BioMérieux (France) – A Key Player.....II-220
1$100
   B. Market Analytics.....II-221
Table 66: French Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-221
2$350
   Table 67: French 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2231$350
   A. Market Analysis.....II-224
Current & Future Analysis.....II-224
Product Launches.....II-224
1$100
   Strategic Corporate Development.....II-225
Epigenomics AG – A Key Player.....II-225
1$100
   B. Market Analytics.....II-226
Table 68: German Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-226
2$350
   Table 69: German 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2281$350
   A. Market Analysis.....II-229
Current & Future Analysis.....II-229
Strategic Corporate Developments.....II-229
1$100
   B. Market Analytics.....II-230
Table 70: Italian Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-230
2$350
   Table 71: Italian 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2321$350
   A. Market Analysis.....II-233
Current & Future Analysis.....II-233
Product Launches.....II-233
2$125
   Strategic Corporate Developments.....II-2354$175
   Focus on Select Major Players.....II-2391$100
   B. Market Analytics.....II-240
Table 72: The UK Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-240
2$350
   Table 73: The UK 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2421$350
   A. Market Analysis.....II-243
Current & Future Analysis.....II-243
Product Launches.....II-243
2$125
   Strategic Corporate Developments.....II-2453$150
   Focus on Select Major Players.....II-2482$125
   B. Market Analytics.....II-250
Table 74: Rest of European Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-250
2$350
   Table 75: Rest of European 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2521$350
   A. Market Analysis.....II-253
Current & Future Analysis.....II-253
Product Launches.....II-253
1$100
   Strategic Corporate Developments.....II-2542$125
   B. Market Analytics.....II-256
Table 76: Asia-Pacific Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-256
2$350
   Table 77: Asia-Pacific 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Servicesz [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2581$350
   A. Market Analysis.....II-259
Current & Future Analysis.....II-259
Strategic Corporate Development.....II-259
Compugen Ltd. (Israel)- A Key Player.....II-259
1$100
   B. Market Analytics.....II-260
Table 78: Rest of World Recent Past, Current and Future Analysis for Biomarkers by Segment - Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart).....II-260
2$350
   Table 79: Rest of World 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart).....II-2621$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com